eedless to say, heart transplantation is the only complete solution for stage D heart failure (HF), which is refractory and requires specialized interventions, 1 but even in the USA where there are more than 2,000 transplantation cases per year, 2 not all stage D patients are able to undergo transplantation immediately and most of them have to wait. Successful bridge-to-transplantation (BTT) results in a good prognosis after heart transplantation, but the longer the waiting period, the harder it is to maintain stable hemodynamics. Temporary mechanical support, such as an intraaortic balloon pump (IABP) or percutaneous cardiopulmonary support (PCPS), is usually available for less than 2 weeks. To secure the minimally required cardiac output over months or sometimes years, the best technique is implantation of a (left) ventricular assist device ([L]VAD). Although the worldwide trend is definitely toward implantable continuous flow VADs, 3,4 the situation in Japan has hardly changed since the early 1990s. The extracorporeal pulsatile TOYOBO VAD 5 was approved by the national government in 1990, but it is still the only device available as of August 2010. Most patients implanted with the TOYOBO VAD have to be in hospital for more than 2 years because of prohibited usage of this device outside of hospitals and the extreme shortage of donor hearts in Japan.
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Currently, we run a heart transplantation program as one of the government-certified institutes in Japan, and since 2002 not a few stage D patients have been referred, many of whom have had a TOYOBO VAD implanted. 6 To determine the best indication for a VAD, the analysis of risk factors affecting prognosis should be indispensable for VAD candidates, 7-11 but because of the unusual VAD circumstances in Japan, the published data from the US and Europe for BTT are not applicable to the TOYOBO VAD because the waiting period before transplantation is normally 2-3 months in those reports. 3,10,12-17 Since 2002, VAD implantation has also been used in the US as terminal care for end-stage HF patients who are not eligible for transplantation; that is, destination therapy SHIGA T et al.
(DT). 18 DT data are based on a longer observation period, similar to that with the TOYOBO VAD, but DT patients are significantly older and have more impaired end-organ function than patients who are eligible for transplantation. 4, 18, 19 Thus, data associated with the use of the TOYOBO VAD would be unique, because we can observe a remote prognosis in BTT patients but there is little solid evidence for the TOYOBO VAD, which leads to debate on the indications for implantation. Therefore, in this study, we examined the survival rate of patients implanted with a TOYOBO VAD from 2002 to 2010 and which preoperative factors were responsible for the worse prognosis.
Methods

Patient Population
We researched 51 consecutive patients with end-stage HF who were treated with a TOYOBO VAD between November 2002 and February 2010 and followed at the University of Tokyo Hospital. We excluded 4 patients whose data were insufficient for analysis, so finally we analyzed the data for 47 patients (age 38.6±14.6 years, male 74.5%, non-ischemic HF 74.5%).
All the patients were treated with general optimal medical therapy (digoxin, diuretics, β-blockers, angiotensin-converting enzyme inhibitors unless intolerant) before TOYOBO VAD implantation. Patients were treated with cardiac resynchronization therapy, if indicated. We usually decided to implant a TOYOBO VAD if the patient developed cardiogenic shock or there was progressive decline of end-organ function because of low cardiac output despite treatment with intravenous inotropic agents. Support with PCPS, IABP, and/or continuous hemodiafiltration was introduced if necessary.
Every patient was considered as eligible for transplantation, at least at the time of TOYOBO VAD implantation. Written informed consent was given before implantation. The study protocol was approved by the Ethics Committee of Graduate School of Medicine, the University of Tokyo [application number 779 (1)].
Some patients required a right VAD (RVAD) in addition to a LVAD perioperatively (ie, a biventricular assist device [BiVAD] ). RVAD therapy included an extracorporeal membranous oxygenation system and/or the TOYOBO VAD inserted in the right ventricle or atrium.
A retrospective analysis of the preoperative clinical, echocardiographic, laboratory, and hemodynamic data was performed to determine the patients' clinical characteristics and to determine the risk factors for death after TOYOBO VAD implantation. Three endpoints were defined: death, explantation of TOYOBO VAD, alive with TOYOBO VAD.
Definition of Patients' Profiles
We classified each patient according to their hemodynamic status at the time of TOYOBO VAD implantation (ie, profile 1 [critical cardiogenic shock] and profile 2 [progressive decline with a use of a continuous intravenous inotrope]), based on the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory support: www.intermacs.org) classification. Patients supported by PCPS were all assigned to profile 1, as were patients who were dependent on IABP. We sometimes inserted a IABP in patients without cardiogenic shock in order to maintain stable hemodynamics until the scheduled VAD implantation and these patients were assigned to profile 2.
Stratification by the Level of Total Bilirubin (Tbil) We stratified patients by the level of serum Tbil to evaluate the relationship between death and the extent of liver damage. We set 3 levels of Tbil (≤2.0 mg/dl, 2.0-5.0 mg/dl, and ≥5.0 mg/dl) because Tbil >2.0 mg/dl has been reported as an independent risk factor for postoperative development of right ventricular HF. 11
Statistical Analysis
We performed a statistical analysis with PASW Statistics 18 (SPSS Inc, Chicago, IL, USA). Continuous variables are expressed as means ± SD and compared using unpaired t-tests. Categorical variables are expressed as percentages and compared using the χ2 test. Kaplan-Meier analysis was used to estimate survival and survival between groups was compared by log-rank test. Univariate and multivariate analyses with a Cox hazard model were performed to calculate the adjusted odds ratio (OR) and 95% confidence interval (CI) to assess the association between death after TOYOBO VAD implantation and each clinical variable. Variables that were found to be significant (P<0.05) in the univariate analysis were entered into the multivariate analysis. If continuous and categorical variables were both significant in the univariate analysis, we chose the continuous one. Probability was 2-tailed, with P<0.05 regarded as statistically significant.
Results
Patients' Baseline Characteristics
We enrolled 47 patients who were treated with a TOYOBO Right ventricular assist device, n (%) 8 (17.0)
NYHA class IV, n (%) 47 (100) Values are means ± SD when appropriate. Dilated cardiomyopathy included patients in the dilated phase of hypertrophic cardiomyopathy. The other causes of heart failure were restrictive cardiomyopathy (1), fulminant myocarditis (2), postpartum cardiomyopathy (2), valvular heart disease (2), adriamycininduced cardiomyopathy (1) and congenital heart disease (1). LVAD, left ventricular assist device; LV, left ventricular; NYHA, New York Heart Association.
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VAD between November 2002 and February 2010 and who could be followed at the University of Tokyo Hospital until the time of their endpoints.
The baseline characteristics of all 47 patients are shown in Table 1 . All patients had New York Heart Association class IV symptoms and most had non-ischemic cardiomyopathy (74.5%). Mean age was 38.6±14.6 years, and there were 35 males (74.5%). Mean support period with a TOYOBO VAD was 407.1±314.3 days. Mean levels of serum C-reactive protein, plasma B-type natriuretic peptide, serum creatinine and Tbil, and the activated partial thromboplastin time (APTT) were above the normal ranges. Average value of left ventricular ejection fraction by echocardiography, and concentrations of serum sodium, hemoglobin, total protein, and albumin were lower than normal. In the present study, there were 8 patients who needed RVAD therapy (17.0%). The number of patients who were finally transplanted was 12 (25.5%). Other endpoints were: death: 14 (29.8%), explantation of TOYOBO VAD with recovery of cardiac function: 6 (12.8%), and alive with TOYOBO VAD: 15 (31.9%).
The baseline characteristics of the 2 profiles are shown in Table 2 . Profile 1 was assigned to 33 (70.2%) patients. Mean left ventricle ejection fraction, serum total protein, serum albumin and Tbil levels, platelet count and APTT were sig- 
nificantly different between profiles.
Patients' Survival
The overall survival after TOYOBO VAD implantation was 93.6%, 83.0%, 73.1%, and 67.0% at 1 month, 3 month, 1 year, and 2 years, respectively (Figure 1) . The mean survival after TOYOBO VAD implantation was 407.0±314.3 days (range 16-1,132 days). As shown in Figure 2 , survival of patients with profile 1 decreased dramatically within the first 3 months (66.3% at 137 days). Patients with profile 2 had a significantly better prognosis (P=0.036) and none of them died within 600 days.
Multiple organ failure (42.9%) and sepsis (28.6%) were the main causes of postoperative death after TOYOBO VAD implantation. Notably, all deaths within the first 3 months was from multiple organ failure, except for 1 patient.
Univariate and Multivariate Analyses for Death After TOYOBO VAD Implantation
Univariate and multivariate analyses of the preoperative risk factors for death after TOYOBO VAD implantation are shown in Tables 3 and 4. In the univariate analysis with a Cox hazard model, we found that the following variables were significantly associated with death: age, serum total protein level, serum albumin level, Tbil level, and APTT. Perioperative need for RVAD was also significantly associated with a poor prognosis.
To determine the risk factors associated with death after TOYOBO VAD implantation, we performed a multivariate analysis with a Cox hazard model, enrolling RVAD and total protein, albumin and Tbil levels and APTT. This analysis revealed that age (OR 1.076, 95%CI 1.045-1.140, P=0.013), RVAD (OR 6.350, 95%CI 1.453-27.757, P=0.014), Tbil (OR 1.312, 95%CI 1.126-1.529, P<0.001) and APTT (OR 1.013, 95%CI 1.001-1.026, P=0.040) were independent risk factors associated with death after TOYOBO VAD implantation. Figure 3 depicts the estimated survival curves stratified by the preoperative Tbil level in patients for whom Tbil data were available (>5.0 mg/dl: n=10; 2.0-5.0 mg/dl, n=11; <2.0 mg/dl, n=24). The survival of patients whose serum Tbil level was greater than 5.0 mg/dl was significantly worse compared with the patients whose Tbil was less than 2.0 mg/dl (P=0.008).
Stratification of Survival by the Level of Tbil
Comparison of Survival Between LVAD and BiVAD Patients
We compared the survival of LVAD and BiVAD patients with Kaplan-Meier analysis (Figure 4) and found that the survival rate of BiVAD patients was significantly decreased in the first 3 month after implantation (50.0% vs. 89.7%: BiVAD vs. LVAD survival rate at the first three month, P=0.003 by log-rank test).
Discussion
We examined the long-term prognosis and preoperative independent risk factors for death of patients in Japan with a 
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TOYOBO extracorporeal VAD, and we found that those with cardiogenic shock had a worse prognosis and that patient age and preoperative increases in Tbil were independent risk factors for mortality. Recently, the long-term prognosis for LVAD from the 2 leading institutes in Japan was reported, 20,21 and our results are very consistent with theirs. However, there are several differences in the patients' characteristics and analytical methods. The study from the National Cerebral and Cardiovascular Center (NCVC) 21 did not include a preoperative risk analysis, rather a postoperative risk analysis, whereas in the study from Osaka University, 20 the prognosis was analyzed in association with preoperative risk factors, as we did. Both studies included more than 100 patients, which definitely strengthened the data analyses, but varying numbers of patients were enrolled in terms of device type and implantation era. Patients indicated for implantable LVADs usually have stable preoperative hemodynamics compared with those who need TOYOBO VAD implantation. As clearly shown in the NCVC study, 21 management of the TOYOBO VAD has improved remarkably in this century, so it is important to have recent data exclusively from patients with the TOYOBO VAD. Firstly, the average age of our 47 patients implanted with a TOYOBO VAD was 38.6 years, which is much younger than that of LVAD patients included in BTT trials in the USA and Europe. In Japan, LVAD use for DT has not been approved to date, and so all our patients were eligible for heart transplantation at least at the time of LVAD implantation. The Japanese guideline for heart transplantation recommends that recipients are less than 60 years old. 13 In the Japanese studies, the mean age was 40.2 years (Osaka study 20 ) and 33.9 years (a recent era group in the NCVC study 21 ), similar to our study. In contrast, the BTT trials in Western countries included patients over 60 years, and the average age of patients in those trials was usually high (50-55 years). 3,10,12 -17 In our study, 74.5% of the patients had a nonischemic cause of HF, which was compatible with the approximately 90% of registered patients in the Japan Organ Transplantation network who have a nonischemic background. The high prevalence of a nonischemic cause is characteristic of Japanese BTT patients, and the Japanese studies included 78.3-94.9% of nonischemic HF patients. 20, 21 In contrast, nonischemic cardiomyopathy was recorded in 51-63% of the BTT patients in the US and European trials. 3,10,12-17 According to a Japanese registry for HF patients (JCARE-CARD), 22 there were less patients with an ischemic background (≈32%) compared with similar registries in Western countries, 23,24 but we consider that the high prevalence of nonischemic cardiomyopathy in Japanese BTT patients is primarily because of the lower age limit for transplantation eligibility.
Because of the extreme shortage of donor organs in Japan, the average waiting period after being registered in the Japan Organ Transplantation network is over 800 days and the registered patients are usually on LVAD support during most of that long period. In this study, we observed long-term outcomes in BTT patients with a TOYOBO VAD for over 1 year, which was the standard waiting period for Japanese patients. In contrast, most of the eligible patients can be bridged to transplantation within 1 year after LVAD implantation in the US. For example, in a BTT trial using the HeartMate VE, 14 67% of patients were bridged to transplantation, 4% of devices were removed, and the remaining patients (29%) had died within 1 year. Considering the different circumstances for heart transplantation between Japan and other countries, the results from BTT trials in Western countries are not appropriate references for the long-term prognosis (>1 year) of Japanese patients on LVAD support. On the other hand, outcomes of DT patients can be compared with those of Japanese LVAD patients because of the similarity in the observation period; for example, 1-and 2-year survival rates were ~55% and ~25%, respectively, in the DT trials of the HeartMate VE 18 and XVE, 19 which were both pulsatile as is the TOYOBO VAD. In this study, we observed better 1-year (73.1%) and 2-year (67.0%) survival rates for the TOYOBO VAD, but all patients were in hospital. Japanese studies also report similar results to ours for the long-term prognosis in "low-risk" patients 20 or in the "recent era". 21 The better prognosis in Japanese TOYOBO VAD patients might 
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be attributable to several reasons: thrombi in the pump are visible because the device is extracorporeal, and anticoagulation therapy can be meticulously adjusted because usage of this device outside of hospitals is prohibited and consequently all patients are in hospital. However, the mean age of patients in those DT trials was 60-66 years, which was higher than the present patient population. The older population is mainly because DT trials normally include many patients who are ineligible for transplantation because of age. Moreover, the older population in the DT trials inevitably consists of more patients with an ischemic cause of HF (46-66% vs. 37-46% in BTT), and the patients' characteristics are much different from our patients. Consistent with the Osaka study. 20 we found that age is an independent risk factor for death after LVAD implantation, and it is no surprise that our younger patients had a better long-term prognosis than those in the DT trials.
In the most recent DT trial for HeartMate II, the 1-and 2-year survival rates were reported to be 68% and 58%, respectively. 4 Considering the mean age of the patients was 62 years in that study, the survival rates were surprisingly good. In a BTT trial for HeartMate II. 3,16 the mean age of the enrolled patients was 50 years, and the 18-month survival was much better (72%) than that of any device previously tested. Because the survivors in the BTT trial included 56% of patients who were successfully bridged to transplantation, the survival rate of 72% was not in fact the long-term prognosis for LVAD support. Nevertheless, it is remarkable to note that more than 20% of eligible patients for transplantation were still on support with the HeartMate II in the USA where the average waiting period before transplantation is approximately 90 days for LVAD patients. This result suggests many patients are comfortable with remaining on the support given by HeartMate II rather than undergoing heart transplantation. HeartMate II is now under clinical trial in Japan, and we anticipate superb outcomes after the introduction of this device.
Much information is now available from INTERMACS, which is a large-scale registry for VADs in the US since 2006. In this registry, the preoperative condition of patients is classified into 7 profiles: profile 1: cardiogenic shock (eg, in need of PCPS); profile 2: progressively declining with intravenous inotropes; profile 3: stable with intravenous inotropes. Profiles 1-3 are compatible to status 1 in the Japan Organ Transplantation network registry, but TOYOBO VAD is not normally indicated for patients with profile 3 because the patient's quality of life cannot be improved after implantation with an extracorporeal LVAD. Even in the US, 72% of VADs were implanted in patients with profile 1 or 2 (data from INTERMACS). Therefore, it is important to compare the prognosis after LVAD implantation between patients with profile 1 or profile 2. Consistent with the data from the INTERMACS registry, we found that patients with profile 2 had a significantly better prognosis than those with profile 1. Our study demonstrated that death early after implantation accounted for a large part of the overall death rate, suggesting that preoperative factors greatly influenced the survival rate after TOYOBO VAD implantation. Almost all deaths within the 3 months after implantation resulted from multiple organ failure, which occurred only in the patients with profile 1. Severe organ damage caused by poor or collapsed preoperative hemodynamics could not be recovered even after LVAD implantation in many of patients with cardiogenic shock.
To explore which factors were responsible for the poor prognosis after TOYOBO VAD implantation, we performed a multivariate analysis, which revealed that age, preoperative Tbil level and APTT were independent risk factors. In particular, the preoperative Tbil level (P<0.001) and age (P=0.013) were strongly associated with mortality after TOYOBO VAD implantation. Many biomarkers are susceptible to concomitant treatment (eg, APTT by heparin, creatinine by dialysis), complicated by infection (eg, C-reactive protein, platelet count), or affected by the patient's nutritional status (eg, albumin, total protein), and thus do not directly reflect hemodynamic collapse. Tbil level may be a marker that is specific for liver damage caused by compromised hemodynamics, albeit a higher Tbil level may not only indicate liver congestion but, more importantly, liver injury caused by low cardiac output. Several previous studies have confirmed this, 7-11 but in the Osaka study multivariate analysis failed to show that the preoperative Tbil level was an independent risk factor for mortality. 20 The discrepancy may be attributable to the fact that half of their patients received different types of LVADs, such as implantable LVADs, or the TOYOBO VAD was inserted in the left atrium. We also observed that perioperative right heart support resulted in extremely poor outcomes after TOYOBO VAD implantation, which was consistent with the results of the Osaka study 20 and data from INTERMACS. 9 Because there were only 8 such cases in our study, we were unable to analyze the preoperative risk factors responsible for the necessity of right heart support. Previous studies showed that preoperative levels of creatinine and Tbil were independent risk factors for right heart support, 11,20 suggesting that biventricular dysfunction causes more severe organ failure.
Study Limitations
We acknowledge that our study has several limitations. This study was conducted in a single center, and consequently included a limited number of patients. The J-MACS registry has recently started to collect data of VAD patients from multiple centers, and we are looking forward to more extensive analyses based on large numbers of patients. This study was conducted in a retrospective manner, and, from the ethical point of view, during the post-REMATCH era we could not set a medical treatment group as a control. Nowadays a prospective controlled study can only be feasible when different types of LVADs are compared, such as in the HeartMate II DT trial. 4 We did not include hemodynamic data obtained by right heart catheterization, which might be useful to determine right ventricular function and thus precisely predict the perioperative necessity of right heart support.
Conclusions
According to an analysis of 47 patients implanted with extracorporeal LVADs, we found that TOYOBO VAD implantation resulted in a better prognosis unless the patient had preoperative hemodynamic collapse. Age and the preoperative Tbil level were independent risk factors for mortality after TOYOBO VAD implantation. Preoperative risk stratification is important because the extracorporeal LVAD demands long-term care for years until a donor heart becomes available.
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